Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 08, 2016 11:32 PM ET

Biotechnology

Company Overview of Q Therapeutics, Inc.

Company Overview

Q Therapeutics, Inc., a clinical-stage company, engages in developing human cell-based therapies intended to treat neurodegenerative diseases of the brain and spinal cord. Its product candidate includes Q-Cells that are healthy human glial progenitor cells intended to restore or preserve normal activity of neurons by providing support functions that occur in healthy central nervous system (CNS) tissues. The company develops Q-Cells for application in a range of CNS diseases, including multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as amyotrophic lateral sclerosis, Huntington’s disease, spinal cord injury, st...

615 Arapeen Drive

Suite 102

Salt Lake City, UT 84108

United States

5 Employees

Phone:

801-582-5400

Fax:

801-582-5401

Key Executives for Q Therapeutics, Inc.

Chairman, Chief Executive Officer and President
Age: 57
Chief Financial Officer
Age: 52
Vice President of Research & Development
Regulatory Consultant
Compensation as of Fiscal Year 2015.

Q Therapeutics, Inc. Key Developments

Linda F. Powers Resigns from the Board of Directors of Q Therapeutics, Inc

On December 11, 2015, Linda F. Powers resigned from the Board of Directors of Q Therapeutics, Inc.

Q Therapeutics, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-11-2016 01:45 PM

Q Therapeutics, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-11-2016 01:45 PM. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States.

Q Therapeutics, Inc. Appoints David A. Green as Chief Financial Officer

Q Therapeutics, Inc. announced that effective November 18, 2015, David A. Green was appointed to serve as Chief Financial Officer of the company. Prior to joining Q Therapeutics in 2015, from January 2015 through October 2015, Mr. Green provided consulting services for a variety of healthcare companies regarding transaction strategy and execution. He served as Chief Financial Officer and Co-Head of Sales Operations at Catheter Connections, Inc.

Similar Private Companies By Industry

Company Name Region
Invibio, Inc. United States
Signal Pharmaceuticals, LLC United States
The GID Group, Inc. United States
Flower Genetics LLC United States
Forticell Bioscience, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Q Therapeutics, Inc., please visit www.qthera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.